Evidence for separate involvement of different μ-opioid receptor subtypes in itch and analgesia induced by supraspinal action of opioids

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 667-670

  Andoh, Tsugunobu ^a   Yageta, Yuichi ^a   Konno, Mitsuhiro ^a   Yamaguchi Miyamoto, Tomomi ^a   Takahata, Hiroki ^b   Nojima, Hiroshi ^c   Nemoto, Hideo ^a   Kuraishi, Yasushi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c OHU UNIVERSITY   (Japan)

Author keywords

Itch; Morphine; Morphine 6 glucronide

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; NALOXONAZINE; NALOXONE; RECEPTOR SUBTYPE;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRURITUS; SCRATCHING;

EID: 42349104714     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08004SC     Document Type: Article

References (15)

1. Chaney MA. Side effect of intrathecal and epidural opioids. Can J Anaesth. 1995;42:891-903.
2. Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth. 2003;15:234-239.
3. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001;18:346-357.
4. Ko MC, Naughton NN. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology. 2000;92:795-805.
5. Thomas DA, Williams GM, Iwata K, Kenshalo DR Jr, Dubner R. Multiple effects of morphine on facial scratching in monkeys. Anesth Analg. 1993;77:933-935.
6. Tohda C, Yamaguchi T, Kuraishi Y. Intracisternal injection of opioids induces itch-associated response through μ-opioid receptors in mice. Jpn J Pharmacol. 1997;74:77-82.
7. Pasternak GW, Wood PJ. Multiple mu opiate receptors. Life Sci. 1986;38:1889-1898.
8. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001;22:67-70.
9. Bolan EA, Pan YX, Pasternak GW. Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm. Synapse. 2004;51:11-18.
10. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987;41:2845-2849.
11. Hanna MH, Peat SJ, Knibb AA, Fung C. Disposition of morphine-6- glucuronide and morphine in healthy volunteers. Br J Anaesth. 1991;66:103-107.
12. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989;251:477-483.
13. Paul D, Bodnar RJ, Gistrak MA, Pasternak GW. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol. 1989;168:307-314.
14. Moskowitz AS, Goodman RR. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Res. 1985;360:117-129.
15. Wahlström A, Winblad B, Bixo M, Rane A. Human brain metabolism of morphine and naloxone. Pain. 1988;35:121-127.